Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa

Archives of Pharmacal Research

Volumn 38, Issue 6, 2015, Pages 1080-1089

  Ku, Sae Kwang ^a   Lee, Wonhwa ^b   Kang, Min ^b   Bae, Jong Sup ^b  

^a Daegu Haany University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Aspalathin; Coagulation cascade; Endothelium; Fibrinolysis; Nothofagin

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARGATROBAN; ASPALATHIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING INHIBITOR; HEPARIN; NOTHOFAGIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; PROTHROMBIN A; RIVAROXABAN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WARFARIN; CHALCONE DERIVATIVE; FACTOR IIA; FIBRINOLYTIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FIBRIN POLYMERIZATION; FIBRINOLYSIS; HUMAN; HUMAN CELL; INTERNATIONAL NORMALIZED RATIO; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PH; PLASMA; PROTEIN EXPRESSION; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; C57BL MOUSE; CELL SURVIVAL; DRUG EFFECTS; IN VITRO STUDY; YOUNG ADULT;

ADULT; ANIMALS; BLOOD COAGULATION; CELL SURVIVAL; CHALCONES; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IN VITRO TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION INHIBITORS; PROTHROMBIN; PROTHROMBIN TIME; THROMBIN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84930868252     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0501-7     Document Type: Article

References (35)

1. Altieri, D.C., P.M. Mannucci, and A.M. Capitanio. 1986. Binding of fibrinogen to human monocytes. Journal of Clinical Investigation 78: 968-976.
2. Bae, J.S. 2011. Antithrombotic and profibrinolytic activities of phloroglucinol. Food and Chemical Toxicology 49: 1572-1577.
3. Bae, J.S., and A.R. Rezaie. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thrombosis and Haemostasis 100: 101-109.
4. Dahlback, B. 2000. Blood coagulation. Lancet 355: 1627-1632.
5. Davie, E.W. 1995. Biochemical and molecular aspects of the coagulation cascade. Thrombosis and Haemostasis 74: 1-6.
6. Davie, E.W., K. Fujikawa, and W. Kisiel. 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363-10370.
7. Dejana, E., A. Callioni, A. Quintana, and G. De Gaetano. 1979. Bleeding time in laboratory animals. II: A comparison of different assay conditions in rats. Thrombosis Research 15: 191-197.
8. Despotis, G.J., G. Gravlee, K. Filos, and J. Levy. 1999. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 91: 1122-1151.
9. Esmon, C.T. 2005. The interactions between inflammation and coagulation. British Journal of Haematology 131: 417-430.
10. Fareed, J., I. Thethi, and D. Hoppensteadt. 2012. Old versus new oral anticoagulants: focus on pharmacology. Annual Review of Pharmacology and Toxicology 52: 79-99.
11. Fares, A. 2013. Winter cardiovascular diseases phenomenon. North American Journal of Medical Sciences 5: 266-279.
12. Ghosh, S., M. Ezban, E. Persson, U. Pendurthi, U. Hedner, and L.V. Rao. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. Journal of Thrombosis and Haemostasis 5: 336-346.
13. Hamaguchi, E., T. Takamura, A. Shimizu, and Y. Nagai. 2003. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. Journal of Pharmacology and Experimental Therapeutics 307: 987-994.
14. Harbrecht, U. 2011. Old and new anticoagulants. Hamostaseologie 31: 21-27.
15. Jauch, E.C., J.L. Saver, H.P. Adams Jr, A. Bruno, J.J. Connors, B.M. Demaerschalk, P. Khatri, P.W. Mcmullan Jr, A.I. Qureshi, K. Rosenfield, P.A. Scott, D.R. Summers, D.Z. Wang, M. Wintermark, and H. Yonas. 2013. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44: 870-947.
16. Joubert, E., W.C. Gelderblom, A. Louw, and D. De Beer. 2008. South African herbal teas: Aspalathus linearis, Cyclopia spp. and Athrixia phylicoides-a review. Journal of Ethnopharmacology 119: 376-412.
17. Kazuno, S., M. Yanagida, N. Shindo, and K. Murayama. 2005. Mass spectrometric identification and quantification of glycosyl flavonoids, including dihydrochalcones with neutral loss scan mode. Analytical Biochemistry 347: 182-192.
18. Kim, S.Y., S. Kim, J.M. Kim, E.H. Jho, S. Park, D. Oh, and H.S. Yun-Choi. 2011. PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Reports 44: 140-145.
19. Kim, T.H., S.K. Ku, and J.S. Bae. 2012. Antithrombotic and profibrinolytic activities of eckol and dieckol. Journal of Cellular Biochemistry 113: 2877-2883.
20. Krafczyk, N., F. Woyand, and M.A. Glomb. 2009. Structure-antioxidant relationship of flavonoids from fermented rooibos. Molecular Nutrition & Food Research 53: 635-642.
21. Lee, K.H. 2000. Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutrition 3: 515-522.
22. Lopez, S., F. Peiretti, B. Bonardo, I. Juhan-Vague, and G. Nalbone. 2000. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152: 359-366.
23. Mann, K.G., K. Brummel, and S. Butenas. 2003. What is all that thrombin for? Journal of Thrombosis and Haemostasis 1: 1504-1514.
24. Mckay, D.L., and J.B. Blumberg. 2007. A review of the bioactivity of South African herbal teas: rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia). Phytotherapy Research 21: 1-16.
25. Nakamura, Y., S. Watanabe, N. Miyake, H. Kohno, and T. Osawa. 2003. Dihydrochalcones: evaluation as novel radical scavenging antioxidants. Journal of Agriculture and Food Chemistry 51: 3309-3312.
26. Nowak, P., H.M. Zbikowska, M. Ponczek, J. Kolodziejczyk, and B. Wachowicz. 2007. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thrombosis Research 121: 163-174.
27. Philip-Joet, F., M.C. Alessi, C. Philip-Joet, M. Aillaud, J.R. Barriere, A. Arnaud, and I. Juhan-Vague. 1995. Fibrinolytic and inflammatory processes in pleural effusions. European Respiratory Journal 8: 1352-1356.
28. Quinn, C., J. Hill, and H. Hassouna. 2000. A guide for diagnosis of patients with arterial and venous thrombosis. Clinical Laboratory Science 13: 229-238.
29. Rao, L.V., S.I. Rapaport, and M. Lorenzi. 1988. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71: 791-796.
30. Rezk, B.M., G.R. Haenen, W.J. Van Der Vijgh, and A. Bast. 2002. The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids. Biochemical and Biophysical Research Communications 295: 9-13.
31. Schleef, R.R., M.P. Bevilacqua, M. Sawdey, M.A. Gimbrone Jr, and D.J. Loskutoff. 1988. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Journal of Biological Chemistry 263: 5797-5803.
32. Schouten, M., W.J. Wiersinga, M. Levi, and T. Van Der Poll. 2008. Inflammation, endothelium, and coagulation in sepsis. Journal of Leukocyte Biology 83: 536-545.
33. Snijman, P.W., E. Joubert, D. Ferreira, X.C. Li, Y. Ding, I.R. Green, and W.C. Gelderblom. 2009. Antioxidant activity of the dihydrochalcones Aspalathin and Nothofagin and their corresponding flavones in relation to other Rooibos (Aspalathus linearis) Flavonoids, Epigallocatechin Gallate, and Trolox. Journal of Agriculture and Food Chemistry 57: 6678-6684.
34. Sugo, T., C. Nakamikawa, S. Tanabe, and M. Matsuda. 1995. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. Journal of Biochemistry 117: 244-250.
35. Weitz, J.I., J. Hirsh, and M.M. Samama. 2004. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 265S-286S.